Clinical Trial Search

Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03

Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms

Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443

Primary: Difference in Mean CKD Register Patient eGFRs Between Groups After 3.5 Years of Study — -2.00; -2.29 mean average eGFR change/mL/min/1.73 m^2

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms

Primary: Changes in Intermuscular Fat Deposition as Assessed by Magnetic Resonance Imaging (MRI). — -0.009 fat/muscle ratio

Primary: Composite Global Cognitive Function — .15; .02 Z-score

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to 6 Months — -8.5; -8.4 % change from preoperative eGFR

Primary: Change in Flow-mediated Dilation (FMD) — 1.1; -0.9 change in percent flow-mediated dilation

Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants

Primary: Difference in 24 Hour Ambulatory Systolic Blood Pressure — 7.7; 12.5 mm Hg

Primary: Platelet Reactivity Measured by Vasodilator Stimulated Phosphoprotein (VASP) Platelet Reactivity Index (PRI %) — 25; 32; 31; 38 PRI% — p=0.105

Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale